|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-6-22
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
This randomized, phase II study assessed the activity of oblimersen sodium, a Bcl-2 antisense oligonucleotide, administered before docetaxel (Taxotere) to patients with castration-resistant prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:CalabroFF,
pubmed-author:CarpentierPP,
pubmed-author:CollettiPP,
pubmed-author:DaugaardGG,
pubmed-author:DumetRR,
pubmed-author:EORTC Genitourinary Tract Cancer Group,
pubmed-author:GilTT,
pubmed-author:GrahamJJ,
pubmed-author:LacombeDD,
pubmed-author:SellaAA,
pubmed-author:SkonecznaII,
pubmed-author:SternbergC NCN,
pubmed-author:Van PoppelHH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1264-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19297314-Aged,
pubmed-meshheading:19297314-Aged, 80 and over,
pubmed-meshheading:19297314-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19297314-Castration,
pubmed-meshheading:19297314-Dose-Response Relationship, Drug,
pubmed-meshheading:19297314-Drug Administration Schedule,
pubmed-meshheading:19297314-Humans,
pubmed-meshheading:19297314-Infusions, Intravenous,
pubmed-meshheading:19297314-Male,
pubmed-meshheading:19297314-Middle Aged,
pubmed-meshheading:19297314-Prostate-Specific Antigen,
pubmed-meshheading:19297314-Prostatic Neoplasms,
pubmed-meshheading:19297314-Taxoids,
pubmed-meshheading:19297314-Thionucleotides,
pubmed-meshheading:19297314-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. cstern@mclink.it
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
